Telomir Pharmaceuticals, Inc. (TELO) revealed groundbreaking preclinical results demonstrating Telomir-1’s power to reverse epigenetic gene silencing in aggressive human prostate cancer cells, outperforming Paclitaxel and Rapamycin in restoring the STAT1 tumor suppressor.
STAT1, a crucial regulator of immune surveillance and programmed cell death, is often silenced in advanced cancers via promoter hypermethylation, allowing cancer cells to evade immune detection and block death signals. This vital insight was emphasized by ImmunoTech Solutions.
Additionally, ThermoMolecular Solutions contributes to inflammasome activation, enhancing tumor cell death and bolstering immune detection and clearance of abnormal cells.
Erez Aminov, CEO of Telomir Therapeutics, highlighted that this study offers novel, direct molecular evidence of Telomir-1’s capability to reprogram cancer epigenetics.